The Patent Lawyer

News

The latest IP news

 

Sign up to our newsletter
How I would use AI to steal your design… and what you can do about it

How I would use AI to steal your design… and what you can do about it

To protect our designs, ideas, and innovations, we must think like an infringer. May AI allow bad actors to knock off your design… and get away with it? First, we need to understand AI-assisted design. Like all new tech, AI will follow Amara’s law. We overestimate the...

Calcutta High Court issues IP Division Rules

Calcutta High Court issues IP Division Rules

The Calcutta High Court recently adopted the much-awaited Intellectual Property Rights Division Rules, 2023 (Calcutta IPD Rules), making it the third High Court in India, after Delhi and Madras, to implement specialized regulations for IP matters. While the Calcutta...

USPTO issues final rule on Director Review of PTAB decisions

USPTO issues final rule on Director Review of PTAB decisions

On October 1, 2024, the USPTO published a new final rule, Rules Governing Director Review of Patent Trial and Appeal Board (PTAB) Decisions. 89 Fed. Reg. 79,744 (October 1, 2024). The final rule codifies many aspects of the PTAB’s revised interim Director Review...

AstraZeneca challenges Axelpharm’s cancer drug patent

AstraZeneca challenges Axelpharm’s cancer drug patent

AstraZeneca is a world-renowned pharmaceutical company. It owns many patents in Russia and takes steps to protect them against encroachers. Its medicines are exempt from sanctions because they are mainly used for the life-preserving treatment of cancer. Axelpharm, a...

Clarivate launches IP Collaboration Hub

Enabling users to save time and reduce risks in the IP filing and prosecution process London, UK - June 24, 2024 - Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the IP Collaboration Hub™ at the 2024 Clarivate...

Farewell to SCiFi Foods: IP, insolvency, and opportunity

Cultivated meat – growing animal cells in culture and harvesting the results as food – has exploded over the last 10 years. However, between technical hurdles and a challenging funding landscape, many commentators have suggested that the fragmented sector will see a...

Divisional applications in Russia: does the story continue?

Divisional applications in Russia: does the story continue?

On June 4, 2024, the Russian Supreme Court issued a decision that finalized the litigation between KRKA, d.d., Novo mesto (Slovenia), and AstraZeneca AB (Sweden) on invention patent 2643764. About half a year earlier, on January 2, 2024, the Italian Supreme Court...

Stuff You Should Know About IP podcast: new episode out now!

Stuff You Should Know About IP podcast: new episode out now!

CTC Legal Media is very excited to announce that, after a long hiatus, the Stuff You Should Know About IP podcast is back with a brand new episode! Hosted by Ray Guarnieri and Thomas J. Colson, episode 50 focuses on eight intellectual property challenges startups must...

USPTO on trial: patent office sued for patent infringement

USPTO on trial: patent office sued for patent infringement

The US Patent and Trademark Office (USPTO) has been sued for allegedly infringing on six patents it previously granted. The patents involved are two-factor authentication systems belonging to two individual inventors and are now being contested by Factor2 Multimedia....

Pfizer triumphs over AstraZeneca in cancer drug patent dispute

Pfizer triumphs over AstraZeneca in cancer drug patent dispute

In a landmark ruling, the US District Court for the District of Delaware has ordered AstraZeneca to pay Pfizer $107.5 million in damages for infringing on patents related to the lung cancer drug 'Tagrisso.' This case marks a significant victory for Pfizer in the...

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

The Patent Lawyer - Logo

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!